Eli Lilly and Company has announced plans to significantly increase its investment in U.S. drug manufacturing, with a commitment of at least $27 billion. This decision comes as a response to potential tariffs on pharmaceuticals threatened by former President Donald Trump. The move aims to more than double the company’s manufacturing investments since 2020, exceeding a total of $50 billion. This strategic shift underscores a new era of ‘Made in America’ drug production, positioning the U.S. as a central hub for pharmaceutical manufacturing. — news from Axios